Wonderful Services!
Good Job! Keep it up!
It's 100% safe. The test does not expose the mother or the child to any risk
Reports come out in 7 working days
It's painless
The accuracy of the test is higher than that of the ultrasound gender test. Accuracy is 97% before week 20 and 99.9% after week 20
Testing can be done from as early as week 8 of pregnancy
We have convenient appointments to suit your schedule
Unlike the invasive test where the amniotic fluid sample from the mother is drawn using amniocentesis, only the maternal blood is used in this test and fetal DNA is obtained from the maternal blood.
The test has been scientifically validated and approved and is done using the most advanced scientific methods and DNA high-sequencing instruments. A rigorous bioinformatics analysis helps to provide accurate and reliable results. You can click here to read the publication
Extracted cffDNA can be analyzed to check whether the fetus is at risk of developing chromosomal disorders such as Down’s Syndrome
The rhesus D status of the fetus can be determined thereby preventing hemolytic disease of the newborn (HDNB) or preventing the unnecessary use of Anti-D
1200
3210
3781
99
%Every DNA test involves sensitive information. Our clients value accuracy, confidentiality and professional service throughout the process.
Good Job! Keep it up!
Good job and well handled.
I am a happy customer.
Thank you for the good work!
Handled in a professional and timely manner.
Very good service before, during, and after. Keep up the good job!
Great job done. Good service.
Friendly staff, privacy respected, exceptionally privately located.
Quick and great service, accurate and reliable results.
KIBS and our work in DNA and genetic testing have featured in Kenyan media.
Daily Nation explores the growth of paternity testing in Kenya and the increasing demand for DNA testing services.
Read the storyKIBS was featured in The Star in an article discussing DNA testing and sample requirements.
Read the storyKIBS has also been featured in People's Daily in coverage involving DNA and identification.
Read the story